Daniel L. Gustafson
Department of Pharmaceutical Sciences and The Cancer Center
University of Colorado Health Sciences Center
4200 E. Ninth Avenue
C-238
USA
Name/email consistency: high
- Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing. Gustafson, D.L., Bradshaw-Pierce, E.L., Merz, A.L., Zirrolli, J.A. J. Pharmacol. Exp. Ther. (2006)
- Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Gustafson, D.L., Merz, A.L., Long, M.E. Cancer Lett. (2005)
- P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. Gustafson, D.L., Long, M.E., Bradshaw, E.L., Merz, A.L., Kerzic, P.J. Cancer Chemother. Pharmacol. (2005)
- Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo. Gustafson, D.L., Siegel, D., Rastatter, J.C., Merz, A.L., Parpal, J.C., Kepa, J.K., Ross, D., Long, M.E. J. Pharmacol. Exp. Ther. (2003)
- Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Gustafson, D.L., Long, M.E., Zirrolli, J.A., Duncan, M.W., Holden, S.N., Pierson, A.S., Eckhardt, S.G. Cancer Chemother. Pharmacol. (2003)
- Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. Gustafson, D.L., Rastatter, J.C., Colombo, T., Long, M.E. J. Pharm. Sci (2002)
- Alterations in P-glycoprotein expression in mouse tissues by doxorubicin: implications for pharmacokinetics in multiple dosing regimens. Gustafson, D.L., Long, M.E. Chem. Biol. Interact. (2001)